Brooks Laboratories Ltd.

₹57.86

-3.2 (-5.3%)

BROOKS Share Price

Pharmaceuticals & Biotechnology

As on October 23, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 170.91 Cr

P/E Ratio6.93

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	62.47	Bearish
10-DMA	65.19	Bearish
20-DMA	61.81	Bearish
50-DMA	62.5	Bearish
100-DMA	64.84	Bearish
200-DMA	63.75	Bearish

Historical Performance

1 Year

-52.4%

3 Years

-48%

5 Years

-52.3%

10 Years

-58.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	857	826	795	632	912
Total Expenditure	787	812	764	896	1,054
Other Income	12	45	11	2	8
Operating Profit	82	58	42	-262	-134
Interest	8	10	8	22	31
Depreciation	16	16	18	70	74
Profit Before Tax	246	-98	-196	-384	-239
Consolidated Net Profit	246	-100	-196	-209	-113
Adjusted EPS	8	-3	-7	-8	-5

Compounded Sales Growth

10 Years:2.1

5 Years:2.1

3 Years:6.3

TTM:0.8

Compounded Profit Growth

10 Years:-15.2

5 Years:-15.2

3 Years:-16.4

TTM:-3.1

Stock Price CAGR

10 Years:-9.1

5 Years:-13.8

3 Years:-19.6

TTM:-49

Return on Equity

10 Years:N/A

5 Years:-4.5

3 Years:-7.5

last year:8.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	295	295	262	247	247
Total Reserves	932	686	393	493	628
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	37	27	18	26	114
Other Current Liabilities	33	24	19	27	88
Short Term Borrowings	59	59	50	57	110
Total Liabilities	1,482	1,237	904	1,096	1,946
Capital Work in Progress	12	---	---	---	151
Long Term Loans & Advances	26	22	27	28	80
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	22	22	26	21	106
Total Current Assets	374	339	310	276	612
Total Assets	1,482	1,237	904	1,096	1,946
Adjusted Book Value	42	33	25	30	35

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of 6.93, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -19.0%, indicating poor shareholder returns.
The stock carries a high beta of 1.4, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹82 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹857 million, indicating a relatively small business scale.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 510679.6

No. of Shares: 8826 (Approx)

Performance:-48.9%

-489320.4

NIFTY Performance: -12.4%

1 day Top Gainers